The Conversation (0)
Marina Biotech announced the appointment of Isaac Blech to its board of directors.
Marina Biotech (OTCQB:MRNA) announced the appointment of Isaac Blech to its board of directors.
As quoted in the press release:
Additionally Marina Biotech also has entered into a Note Purchase Agreement with a trust affiliated with Mr. Blech pursuant to which the Company will issue a secured convertible promissory note in the aggregate principal amount of $500,000. The Note will become due and payable on March 31, 2018.
“We are honored to have such an accomplished biotech entrepreneur and investor such as Isaac joining our Board,” Dr. Vuong Trieu, Executive Chairman of Marina Biotech, stated. “Isaac’s impressive track record in helping to create and grow leading companies will be instrumental at this critical point in our company history. His involvement will allow us to move forward with the commercialization of our FDA-approved product Prestalia, and other innovative drugs for the treatment of hypertension, of which more than half of the 75 million patients are still struggling to achieve blood pressure control.”
Click here to read the full press release.
Source: globenewswire.com
